» Articles » PMID: 36874028

Luteolin Protects DYT- Cells from Apoptosis by Suppressing PKR Activation

Overview
Journal Front Pharmacol
Date 2023 Mar 6
PMID 36874028
Authors
Affiliations
Soon will be listed here.
Abstract

DYT- is a movement disorder caused by mutations in the gene, which encodes for PACT, the protein activator of interferon-induced, double-stranded RNA (dsRNA)-activated protein kinase PKR. PACT brings about PKR's catalytic activation by a direct binding in response to stress signals and activated PKR phosphorylates the translation initiation factor eIF2α. Phosphorylation of eIF2α is the central regulatory event that is part of the integrated stress response (ISR), an evolutionarily conserved intracellular signaling network essential for adapting to environmental stresses to maintain healthy cells. A dysregulation of either the level or the duration of eIF2α phosphorylation in response to stress signals causes the normally pro-survival ISR to become pro-apoptotic. Our research has established that the mutations reported to cause DYT- lead to enhanced PACT-PKR interactions causing a dysregulation of ISR and an increased sensitivity to apoptosis. We have previously identified luteolin, a plant flavonoid, as an inhibitor of the PACT-PKR interaction using high-throughput screening of chemical libraries. Our results presented in this study indicate that luteolin is markedly effective in disrupting the pathological PACT-PKR interactions to protect DYT- cells against apoptosis, thus suggesting a therapeutic option for using luteolin to treat DYT- and possibly other diseases resulting from enhanced PACT-PKR interactions.

Citing Articles

Luteolin Is a Potential Immunomodulating Natural Compound against Pulpal Inflammation.

Kawakami K, Fukuda T, Toyoda M, Nakao Y, Hayashi C, Watanabe Y Biomed Res Int. 2024; 2024:8864513.

PMID: 38304347 PMC: 10834097. DOI: 10.1155/2024/8864513.


PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway.

Qiu J, Feng M, Yang G, Su D, Zhao F, Liu Y Heliyon. 2023; 9(6):e17194.

PMID: 37484321 PMC: 10361375. DOI: 10.1016/j.heliyon.2023.e17194.

References
1.
Oliveira Dos Santos C, Pereira da Silva-Junior F, Puga R, Barbosa E, Azevedo Silva S, Borges V . The prevalence of PRKRA mutations in idiopathic dystonia. Parkinsonism Relat Disord. 2017; 48:93-96. DOI: 10.1016/j.parkreldis.2017.12.015. View

2.
Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman A . The integrated stress response. EMBO Rep. 2016; 17(10):1374-1395. PMC: 5048378. DOI: 10.15252/embr.201642195. View

3.
Li Y, Xiao J, Tan Y, Wang J, Zhang Y, Deng X . Inhibition of PKR ameliorates lipopolysaccharide-induced acute lung injury by suppressing NF-κB pathway in mice. Immunopharmacol Immunotoxicol. 2017; 39(4):165-172. DOI: 10.1080/08923973.2017.1303839. View

4.
Cole J . Activation of PKR: an open and shut case?. Trends Biochem Sci. 2007; 32(2):57-62. PMC: 2703476. DOI: 10.1016/j.tibs.2006.12.003. View

5.
Kuipers D, Mandemakers W, Lu C, Olgiati S, Breedveld G, Fevga C . EIF2AK2 Missense Variants Associated with Early Onset Generalized Dystonia. Ann Neurol. 2020; 89(3):485-497. PMC: 7986743. DOI: 10.1002/ana.25973. View